MICA/MICB
Assets acting on this target.
- Class
- MICA/MICB-targeting monoclonal antibody
- Notes
- audit finding #1642 (material); source: https://clinicaltrials.gov/api/v2/studies/NCT05117476
Assets acting on this target.
1 of 1 assets (1 discontinued)
| Drug | Owner | Mechanism | Indication | Reached | Why it stopped | Source |
|---|---|---|---|---|---|---|
| Isuventatug | Cullinan Therapeutics Inc. | MICA/MICB | Non-Small Cell Lung Cancer | Ph 1 | CLN-619, Cullinan Therapeutics' anti-MICA/B antibody, is in an active Phase 1 trial (NCT05117476) with an NSCLC expansion cohort showing objective responses and clinical benefit in oncogene-mutant NSCLC patients as of the company's 2024-2025 data updates. | source ↗ |